His primary scientific interests are in Multiple sclerosis, Internal medicine, Expanded Disability Status Scale, Physical therapy and Natalizumab. His Multiple sclerosis study is concerned with the larger field of Immunology. His Expanded Disability Status Scale course of study focuses on Pregnancy and Young adult and Interquartile range.
His Physical therapy study also includes
His primary areas of investigation include Multiple sclerosis, Internal medicine, Natalizumab, Expanded Disability Status Scale and Fingolimod. His Multiple sclerosis study deals with the bigger picture of Immunology. His work on Oncology expands to the thematically related Internal medicine.
His research integrates issues of Alemtuzumab, Adverse effect, Discontinuation and Relapsing remitting in his study of Natalizumab. His study in Expanded Disability Status Scale is interdisciplinary in nature, drawing from both Prospective cohort study and Incidence. The concepts of his Cohort study study are interwoven with issues in Severity of illness and Confidence interval.
His main research concerns Multiple sclerosis, Internal medicine, Natalizumab, Cohort and Cohort study. Many of his research projects under Multiple sclerosis are closely connected to Clinical neurology with Clinical neurology, tying the diverse disciplines of science together. His work focuses on many connections between Internal medicine and other disciplines, such as Oncology, that overlap with his field of interest in Relapsing remitting.
His Natalizumab research includes themes of Fingolimod, Adverse effect, Discontinuation and Ocrelizumab. Helmut Butzkueven focuses mostly in the field of Cohort, narrowing it down to matters related to Proportional hazards model and, in some cases, Clinically isolated syndrome and Gestation. His Cohort study research incorporates themes from Pregnancy, Alemtuzumab, Quartile and Obstetrics.
Helmut Butzkueven focuses on Multiple sclerosis, Cohort study, Internal medicine, Natalizumab and Fingolimod. Multiple sclerosis connects with themes related to Family medicine in his study. The study incorporates disciplines such as Pregnancy, Disease and Obstetrics in addition to Cohort study.
His research investigates the connection between Internal medicine and topics such as Expanded Disability Status Scale that intersect with problems in Confidence interval and Hazard ratio. His research in Natalizumab intersects with topics in Observational study, Alemtuzumab and Glatiramer acetate. His studies deal with areas such as Lower risk and Neurology as well as Glatiramer acetate.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Ashley H. Beecham;Nikolaos A. Patsopoulos;Nikolaos A. Patsopoulos;Dionysia K. Xifara;Mary F. Davis.
Nature Genetics (2013)
Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
R. H.S.R. Roxburgh;S. R. Seaman;T. Masterman;A. E. Hensiek.
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
I. A. F. Van Der Mei;A.-L. Ponsonby;T. Dwyer;L. Blizzard.
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
Clarissa L. Martin;Beverley. Phillips;Trevor. Kilpatrick;Helmut. Butzkueven.
Multiple Sclerosis Journal (2006)
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20
Melanie Bahlo;David R Booth;Simon A Broadley;Matthew A Brown;Matthew A Brown.
Nature Genetics (2009)
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia
I. A. F. van der Mei;A.-L. Ponsonby;T. Dwyer;L. Blizzard.
Journal of Neurology (2007)
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival
Helmut Butzkueven;Jian Guo Zhang;Merja Soilu-Hanninen;Hubertus Hochrein.
Nature Medicine (2002)
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci
Nikolaos A. Patsopoulos;Federica Esposito;Joachim Reischl;Stephan Lehr.
Annals of Neurology (2011)
Brain health: time matters in multiple sclerosis
Gavin Giovannoni;Helmut Butzkueven;Suhayl Dhib-Jalbut;Jeremy Hobart.
Multiple sclerosis and related disorders (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: